"Immunotherapists" are well acquainted with the notion that achieving a long-term disease control and improving survival by modulating the immune system is a reachable goal in a proportion of cancer patients.[@R1] The significant clinical success obtained by a novel class of therapeutic monoclonal antibodies (mAb) that target immune checkpoints is spreading this knowledge and conviction among an ever larger community of oncologists. Along similar lines, the clear-cut therapeutic success achieved in cutaneous melanoma patients by ipilimumab, a mAb specific for blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4), has broadened its therapeutic indications on one hand,[@R2] and has prompted the clinical development of additional checkpoint- blocking mAbs, including molecules that target programmed cell death 1 (PDCD1, best known as PD-1) and its main ligand CD274 (best known as PD-L1), on the other hand.[@R3] Based on accumulating clinical data, a further step into the future will undoubtedly involve the combinatorial and/or sequential administration of multiple checkpoints-blocking mAbs, as well as their association with conventional chemotherapeutic and/or active immunotherapy (e.g., anticancer vaccines).

In spite of the steadily increasing incidence of this disease, the current therapeutic options against malignant mesothelioma (MM) are largely unsatisfactory. The combination of platinum-based chemotherapy and pemetrexed constitutes indeed the standard of care, being associated with a median survival of only 12 mo.[@R4] Furthermore, second-line treatments remain an unsolved issue, since different cytotoxic chemotherapeutic and targeted anticancer agents have failed to exert clinical activity in MM patients.[@R5] Seeking to assess the therapeutic potential of blocking CTLA4 in malignancies previously unexplored in this sense and generally associated with dismal prognosis, we designed the MESOT-TREM-2008 study. In this context, we investigated the clinical and immunological activity of the anti-CTLA4 mAb tremelimumab in unresectable MM patients who failed a first-line platinum-containing chemotherapeutic regimen. The preliminary results of this clinical trial have recently been published in *The Lancet Oncology*.[@R6] Though the primary endpoint of the study (i.e., objective response rate) was not met, 2 out of 29 patients treated with tremelimumab achieved a durable partial response, and 7 had a prolonged stabilization of disease, with a comprehensive disease control rate of 31%. Initial disease progression followed by a long-lasting partial response was observed in one patient ([Fig. 1](#F1){ref-type="fig"}). Such an "unusual" pattern of response has been previously documented in metastatic melanoma patients receiving ipilimumab.[@R7] Thus, our findings corroborate the notion that blocking CTLA4 can lead to "peculiar" clinical responses in patients affected by various tumor types. This implies that a careful assessment of disease progression is mandatory before the discontinuation of anti-CTLA4 therapy, as clinical benefits may be delayed.[@R7] Such an aspect is highly relevant for patients with MM, a setting in which radiological assessments are central in the evaluation of disease progression and response to treatment.[@R8] An additional typical feature of CTLA4 blockade is the induction of persistent disease stabilization. Indeed, a long-lasting stable disease was achieved by 24% of the MM patients enrolled in our study. The 1- and 2-y survival rates that we observed, 48.3% and 36.7%, respectively, compare quite favorably with available data for MM patients.[@R5] Though limited by the small cohort size, our study identified a proportion of MM patients who may obtain long-term clinical benefits from tremelimumab, which is consistent with extensive clinical data collected in metastatic melanoma patients receiving ipilimumab.[@R9]

![**Figure 1.** CT scan of a malignant pleural mesothelioma patient receiving tremelimumab. (**A--D**) Computer tomography (CT) scans were performed at baseline (**A**) and after the second (day 180, **B**), fourth (day 470, **C**), and seventh (day 630, **D**) dose of tremelimumab. The patient achieved a partial response (**C and D**) after initial disease progression was noted at the first (data not shown) and second assessments (**B**).](onci-3-e27482-g1){#F1}

The identification of robust biomarkers that might predict the response of cancer patients to CTLA4-blocking agents is still a major, unsettled topic. In our study, we prospectively demonstrated that the increase in the absolute number of circulating CD4^+^ICOS^+^ T lymphocytes in the very early phases of treatment is predictive of an improved survival. However, the levels of CD4^+^ICOS^+^ T lymphocytes before therapy did not allow for the identification of patients who would experience a favorable disease outcome upon the administration of tremelimumab.[@R6] This finding, which is in line with retrospective data obtained in metastatic melanoma patients treated with ipilimumab,[@R9] suggests that the analysis of circulating CD4^+^ICOS^+^ T lymphocytes might represent a general, dynamic, tool to guide the use of anti-CTLA4 mAbs in patients affected by different tumor types.[@R10]

Though limited by the restricted size of the patient cohort, the MESOT-TREM-2008 study provided initial, and in our view highly encouraging, evidence in support of the clinical and immunological activity of tremelimumab in pre-treated MM patients. To further corroborate these findings, we launched the MESOT-TREM-2012 study (NCT01655888), exploring a more intensive tremelimumab administration schedule in second-line MM patients. The results of this clinical trial are eagerly awaited.

Luana Calabrò declares no conflict of interest; Michele Maio is consultant, advisor, or both, to Bristol-Myers Squibb, Roche-Genetech, and Medimmune.

This work was supported by unrestricted grants from the Associazione Italiana per la Ricerca sul Cancro, Istituto Toscano Tumori.

Previously published online: [www.landesbioscience.com/journals/oncoimmunology/article/27482](http://www.landesbioscience.com/journals/oncoimmunology/article/27482/)

Citation: Calabró L, Maio M. Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?. OncoImmunology 2013; 2:e27482; [10.4161/onci.27482](10.4161/onci.27482)
